PEDS5:Volunteer Assignments and Opportunities - Revision history

Jennelleh at 19:11, 10 September 2024

2024-09-10T19:11:19Z

← Older revision		Revision as of 14:11, 10 September 2024
Line 6:		Line 6:

	To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.		To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.

	__TOC__		__TOC__
	{\| class="wikitable" style="margin:auto"		{\| class="wikitable" style="margin:auto"
Line 18:		Line 19:
	!'''Notes'''		!'''Notes'''
	\|-		\|-
	\|CHAPTER 2 (HAEMATOLYMPHOID DISORDERS)		\|
			==== CHAPTER 2 (HAEMATOLYMPHOID DISORDERS) ====
	\|		\|
	----		----
Line 456:		Line 458:
	\|		\|
	\|-		\|-
	\|CHAPTER 3 (CNS TUMOURS)		\|
			==== CHAPTER 3 (CNS TUMOURS) ====
	\|		\|
	----		----
Line 982:		Line 985:
	\|		\|
	\|-		\|-
	\|CHAPTER 4 (PERIPHERAL NEUROBLASTIC TUMOURS)		\|
			==== CHAPTER 4 (PERIPHERAL NEUROBLASTIC TUMOURS) ====
	\|		\|
	----		----
Line 1,046:		Line 1,050:
	\|		\|
	\|-		\|-
	\|CHAPTER 5 (EYE TUMOURS)		\|
			==== CHAPTER 5 (EYE TUMOURS) ====
	\|		\|
	----		----
Line 1,187:		Line 1,192:
	\|		\|
	\|-		\|-
	\|CHAPTER 6 (SOFT TISSUE AND BONE TUMOURS)		\|
			==== CHAPTER 6 (SOFT TISSUE AND BONE TUMOURS) ====
	\|		\|
	----		----
Line 2,274:		Line 2,280:
	\|		\|
	\|-		\|-
	\|CHAPTER 7 (GERM CELL TUMOURS)		\|
			==== CHAPTER 7 (GERM CELL TUMOURS) ====
	\|		\|
	----		----
Line 2,448:		Line 2,455:
	\|		\|
	\|-		\|-
	\|CHAPTER 8 (RENAL AND MALE GENITAL TUMOURS)		\|
			==== CHAPTER 8 (RENAL AND MALE GENITAL TUMOURS) ====
	\|		\|
	----		----
Line 2,644:		Line 2,652:
	\|		\|
	\|-		\|-
	\|CHAPTER 9 (FEMALE GENITAL TUMOURS)		\|
			==== CHAPTER 9 (FEMALE GENITAL TUMOURS) ====
	\|		\|
	----		----
Line 2,796:		Line 2,805:
	\|		\|
	\|-		\|-
	\|CHAPTER 10 (BREAST TUMOURS)		\|
			==== CHAPTER 10 (BREAST TUMOURS) ====
	\|		\|
	----		----
Line 2,849:		Line 2,859:
	\|		\|
	\|-		\|-
	\|CHAPTER 11 (DIGESTIVE SYSTEM ~~TUMOUR~~)		\|
			==== CHAPTER 11 (DIGESTIVE SYSTEM TUMOURS) ====
	\|		\|
	----		----
Line 3,023:		Line 3,034:
	\|		\|
	\|-		\|-
	\|CHAPTER 12 (ENDOCRINE TUMOURS)		\|
			==== CHAPTER 12 (ENDOCRINE TUMOURS) ====
	\|		\|
	----		----
Line 3,164:		Line 3,176:
	\|		\|
	\|-		\|-
	\|CHAPTER 13 (HEAD AND NECK TUMOURS)		\|
			==== CHAPTER 13 (HEAD AND NECK TUMOURS) ====
	\|		\|
	----		----
Line 3,371:		Line 3,384:
	\|		\|
	\|-		\|-
	\|CHAPTER 14 (THORACIC TUMOURS)		\|
			==== CHAPTER 14 (THORACIC TUMOURS) ====
	\|		\|
	----		----
Line 3,435:		Line 3,449:
	\|		\|
	\|-		\|-
	\|CHAPTER 15 (SKIN TUMOURS)		\|
			==== CHAPTER 15 (SKIN TUMOURS) ====
	\|		\|
	----		----
Line 3,565:		Line 3,580:
	\|		\|
	\|-		\|-
	\|CHAPTER 16 (GENETIC TUMOUR SYNDROMES)		\|
			==== CHAPTER 16 (GENETIC TUMOUR SYNDROMES) ====
	\|		\|
	----		----

Jennelleh at 19:03, 10 September 2024

2024-09-10T19:03:46Z

← Older revision		Revision as of 14:03, 10 September 2024
Line 6:		Line 6:

	To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.		To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
			__TOC__
	{\| class="wikitable" style="margin:auto"		{\| class="wikitable" style="margin:auto"
	\|+<big>WHO Classification of Paediatric Tumours (5th Edition) Content</big>		\|+<big>WHO Classification of Paediatric Tumours (5th Edition) Content</big>

Jennelleh at 21:42, 15 July 2024

2024-07-15T21:42:22Z

← Older revision		Revision as of 16:42, 15 July 2024
Line 3,696:		Line 3,696:
	\|[[PEDS5:Lynch_syndrome\|Lynch syndrome]]		\|[[PEDS5:Lynch_syndrome\|Lynch syndrome]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:Xeroderma_pigmentosum\|Xeroderma pigmentosum]]		\|[[PEDS5:Xeroderma_pigmentosum\|Xeroderma pigmentosum]]

Jennelleh at 22:06, 12 July 2024

2024-07-12T22:06:24Z

← Older revision		Revision as of 17:06, 12 July 2024
Line 3,586:		Line 3,586:
	\|[[PEDS5:Neurofibromatosis_type_1\|Neurofibromatosis type 1]]		\|[[PEDS5:Neurofibromatosis_type_1\|Neurofibromatosis type 1]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:Neurofibromatosis_type_2\|Neurofibromatosis type 2]]		\|[[PEDS5:Neurofibromatosis_type_2\|Neurofibromatosis type 2]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:Tuberous_sclerosis\|Tuberous sclerosis]]		\|[[PEDS5:Tuberous_sclerosis\|Tuberous sclerosis]]

Jennelleh at 20:27, 12 July 2024

2024-07-12T20:27:52Z

← Older revision		Revision as of 15:27, 12 July 2024
Line 3,740:		Line 3,740:
	\|[[PEDS5:DICER1_syndrome\|DICER1 syndrome]]		\|[[PEDS5:DICER1_syndrome\|DICER1 syndrome]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:BAP1_tumour_predisposition_syndrome\|BAP1 tumour predisposition syndrome]]		\|[[PEDS5:BAP1_tumour_predisposition_syndrome\|BAP1 tumour predisposition syndrome]]

Jennelleh at 19:41, 12 July 2024

2024-07-12T19:41:05Z

← Older revision		Revision as of 14:41, 12 July 2024
Line 3,762:		Line 3,762:
	\|[[PEDS5:Constitutional_mismatch_repair_deficiency_syndrome\|Constitutional mismatch repair deficiency syndrome]]		\|[[PEDS5:Constitutional_mismatch_repair_deficiency_syndrome\|Constitutional mismatch repair deficiency syndrome]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:Rhabdoid_tumour_predisposition_syndrome\|Rhabdoid tumour predisposition syndrome]]		\|[[PEDS5:Rhabdoid_tumour_predisposition_syndrome\|Rhabdoid tumour predisposition syndrome]]

Jennelleh at 19:36, 12 July 2024

2024-07-12T19:36:27Z

← Older revision		Revision as of 14:36, 12 July 2024
Line 3,729:		Line 3,729:
	\|[[PEDS5:Li-Fraumeni_syndrome\|Li-Fraumeni syndrome]]		\|[[PEDS5:Li-Fraumeni_syndrome\|Li-Fraumeni syndrome]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:DICER1_syndrome\|DICER1 syndrome]]		\|[[PEDS5:DICER1_syndrome\|DICER1 syndrome]]

Jennelleh at 19:12, 12 July 2024

2024-07-12T19:12:18Z

← Older revision		Revision as of 14:12, 12 July 2024
Line 3,641:		Line 3,641:
	\|[[PEDS5:Von_Hippel-Lindau_syndrome\|Von Hippel-Lindau syndrome]]		\|[[PEDS5:Von_Hippel-Lindau_syndrome\|Von Hippel-Lindau syndrome]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:Hereditary_phaeochromocytoma-paraganglioma_syndromes\|Hereditary phaeochromocytoma-paraganglioma syndromes]]		\|[[PEDS5:Hereditary_phaeochromocytoma-paraganglioma_syndromes\|Hereditary phaeochromocytoma-paraganglioma syndromes]]

Jennelleh at 18:45, 12 July 2024

2024-07-12T18:45:37Z

← Older revision		Revision as of 13:45, 12 July 2024
Line 3,685:		Line 3,685:
	\|[[PEDS5:Familial_adenomatous_polyposis\|Familial adenomatous polyposis]]		\|[[PEDS5:Familial_adenomatous_polyposis\|Familial adenomatous polyposis]]
	\|Disease		\|Disease
	\|		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|		\|N/A
	\|-		\|-
	\|[[PEDS5:Lynch_syndrome\|Lynch syndrome]]		\|[[PEDS5:Lynch_syndrome\|Lynch syndrome]]

Jennelleh at 18:28, 12 July 2024

2024-07-12T18:28:40Z

← Older revision		Revision as of 13:28, 12 July 2024
Line 3,663:		Line 3,663:
	\|[[PEDS5:WAGR_syndrome\|WAGR syndrome]]		\|[[PEDS5:WAGR_syndrome\|WAGR syndrome]]
	\|Disease		\|Disease
	\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]		\|[[GTS5:Volunteer Assignments and Opportunities\|See GTS5 volunteer sheet for authorship status]]
			\|N/A
	\|N/A		\|N/A
	\|N/A		\|N/A
Line 3,670:		Line 3,671:
	\|N/A		\|N/A
	\|N/A		\|N/A
	~~\|See GTS5 book for page~~
	\|-		\|-
	\|[[PEDS5:Beckwith-Wiedemann_and_related_overgrowth_syndromes\|Beckwith-Wiedemann and related overgrowth syndromes]]		\|[[PEDS5:Beckwith-Wiedemann_and_related_overgrowth_syndromes\|Beckwith-Wiedemann and related overgrowth syndromes]]